The METAPAIN project consists of developing and industrialising a medicinal product combining two active ingredients: paracetamol and nefopam for the treatment of moderate and proven pain. The METAPAIN project, therefore, has set itself the objective of developing a new effective antalgic specialty with limited side effects. It is a collaborative project with the University of Clermont Auvergne, the CHU of Clermont-Ferrand and the company UNITHER PHARMACEUTICALS located in Amiens. This project is part of the Strategic Intervention Area “Health and Comfort of Life” of the Intelligent Specialisation Strategy and went to the S3 Project Review Committee. This is only about financing project-related services.